In addition, the laboratory costs differ for all molecular genetic tests with the exception of presymptomatic screening (sequence analysis) for breast and/or ovarian mutations (BRCA1 and BRCA2) and HNPCC mutations (MLH1 and MSH2). This evidence concerns the gene BRCA1 and hereditary nonpolyposis colon cancer.